AV-101

AV-101 (also known as 4-Cl-KYN or L-4-chlorokynurenine) is a prodrug that is converted in the brain into 7-chlorokynurenic acid (7-Cl-KYNA), an antagonist of the NMDA receptor. It is being developed as a treatment for major depressive disorder and neuropathic pain.

Pharmacology

AV-101 is a prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), a potent and selective antagonist of the glycine site of the NMDA receptor. The NMDA receptor is a subtype of glutamate receptor. NMDA receptor antagonists like 7-Cl-KYNA are thought to have potential in the treatment of conditions such as depression, neuropathic pain, and epilepsy, among others.

Clinical trials

AV-101 has been studied in Phase 2 clinical trials for the treatment of major depressive disorder and neuropathic pain. The results of these trials have not yet been published.

See also

• List of investigational antidepressants
• List of investigational analgesics

References

AV-101 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski